CervoMed Inc.

What they do

CervoMed is developing neflamapimod, an investigational oral small-molecule drug that crosses the blood-brain barrier and selectively inhibits the enzyme p38, which the company describes as a key driver of neuroinflammation and synaptic dysfunction. The lead indication is DLB, with additional clinical development in nfvPPA, RAS and ALS. The company is pre-commercial and has no approved products.

Revenue drivers

• No commercial product revenue — The company is clinical-stage with no approved products; quarterly revenue in 2026 has been negligible ($322,569 in Q3 2025, $8,726 in Q4 2025, and $0 in both Q1 and Q2 2026).
• Prior-year revenue — Annual revenue was $7.1M in 2023 and $9.7M in 2024, falling to $4.0M in 2025; the source excerpts do not identify what generated this revenue.
• Equity financings as funding source — In June 2026 the company completed a private placement and a registered direct offering for aggregate gross proceeds of approximately $20.5M, which funds operations rather than representing product revenue.

Recent performance

Second quarter 2026 revenue was $0, following $8,726 in Q4 2025 and $322,569 in Q3 2025. Full-year 2025 revenue was $4.0M versus $9.7M in 2024, while net loss widened to $27.0M in 2025 from $16.3M in 2024. Operating cash use was $23.4M in 2025 versus $16.5M in 2024. As of June 30, 2026, total assets were $26.0M, total liabilities $3.0M, shareholder equity $23.0M and cash and equivalents $22.5M.

Strategy

The primary stated strategic objective is securing a partner to support advancing neflamapimod into Phase 3 for DLB. The company plans to initiate the Phase 3 DLB trial in the second half of 2026. It is also running Phase 2a trials in nfvPPA and RAS, with data readouts expected in 2026 and 2027. In June 2026 it completed two equity financings raising approximately $20.5M gross and says this extends its cash runway through the third quarter of 2027.

Risks

• Going concern — The 10-K states that recurring losses raise substantial doubt about the company's ability to continue as a going concern.
• Need for additional capital — The company has incurred significant losses since inception, expects net losses to continue, and states it will require additional capital to fund operations beyond its current runway.
• Clinical and regulatory risk — Neflamapimod has no approved indication and remains dependent on successful Phase 3 DLB results, which the company has not yet initiated.
• Partnering risk — The stated priority of securing a partner for the Phase 3 DLB program is not yet completed and there is no disclosure of a signed partnership.

Outlook

Management expects to complete enrollment in the Phase 2a nfvPPA trial and the Phase 2a RESTORE trial in RAS by mid-2026, with initial nfvPPA biomarker data in mid-2026 and topline RAS data in the second half of 2026. The company plans to initiate the Phase 3 DLB trial in the second half of 2026 and dose the first ALS patient in the EXPERTS-ALS trial by year-end 2026. Topline Phase 2a nfvPPA clinical and biomarker data are anticipated in the first half of 2027. The company states its cash runway extends through the third quarter of 2027.